Silicon Laboratories (SLAB) Financials

$102.76 -1.12 (-1.08%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$101.88 -0.88 (-0.86%)

As of 04/25/2025 07:58 PM Eastern

Annual Income Statements for Silicon Laboratories

This table shows Silicon Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	30	61	47	84	19	13	2,117	91	-35	-191
Consolidated Net Income / (Loss)	30	61	47	84	19	13	2,117	91	-35	-191
Net Income / (Loss) Continuing Operations	30	61	47	84	-103	-115	-58	91	-35	-191
Total Pre-Tax Income	30	64	77	72	-96	-132	-58	126	-11	-155
Total Operating Income	32	66	85	85	-89	-107	-33	119	-24	-165
Total Gross Profit	381	422	454	521	280	295	425	643	461	312
Total Revenue	645	698	769	868	474	511	721	1,024	782	584
Operating Revenue	645	698	769	868	474	511	721	1,024	782	584
Total Cost of Revenue	264	276	315	347	194	216	295	382	322	272
Operating Cost of Revenue	264	276	315	347	194	216	295	382	322	272
Total Operating Expenses	349	355	369	436	369	402	458	523	485	478
Selling, General & Admin Expense	160	155	160	198	163	167	185	191	147	145
Research & Development Expense	188	200	209	238	206	235	273	332	338	332
Total Other Income / (Expense), net	-1.97	-1.78	-8.07	-13	-7.37	-25	-25	7.19	14	11
Interest Expense	2.83	2.59	14	20	20	34	31	6.72	5.55	1.31
Interest & Investment Income	0.86	0.81	6.06	6.65	13	9.03	5.70	14	19	12
Income Tax Expense	0.68	3.00	30	-11	6.98	-15	13	38	7.94	36
Other Gains / (Losses), net	-	-	-	-	0.32	2.12	14	3.40	-16	0.00
Basic Earnings per Share	$0.70	$1.47	$1.11	$1.94	$0.44	$0.29	$49.44	$2.61	($1.09)	($5.93)
Weighted Average Basic Shares Outstanding	42.31M	41.71M	42.45M	43.16M	43.35M	43.78M	42.83M	35.09M	31.80M	32.19M
Diluted Earnings per Share	$0.69	$1.45	$1.09	$1.90	$0.43	$0.28	$47.78	$2.54	($1.09)	($5.93)
Weighted Average Diluted Shares Outstanding	42.95M	42.38M	43.33M	44.04M	44.29M	44.37M	44.32M	36.04M	31.80M	32.19M
Weighted Average Basic & Diluted Shares Outstanding	42.30M	41.80M	42.40M	557.30M	43.50M	43.93M	38.20M	31.90M	31.90M	32.46M

This table shows Silicon Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	21	25	14	11	10	-70	-57	-82	-29	-24
Consolidated Net Income / (Loss)	21	25	14	11	10	-70	-57	-82	-29	-24
Net Income / (Loss) Continuing Operations	21	25	14	11	10	-70	-57	-82	-29	-24
Total Pre-Tax Income	33	27	23	23	14	-70	-57	-45	-26	-26
Total Operating Income	30	24	20	17	12	-73	-59	-48	-30	-29
Total Gross Profit	166	157	154	144	119	44	55	77	90	90
Total Revenue	270	257	247	245	204	87	106	145	166	166
Operating Revenue	270	257	247	245	204	87	106	145	166	166
Total Cost of Revenue	104	100	93	101	85	43	51	69	76	76
Operating Cost of Revenue	104	100	93	101	85	43	51	69	76	76
Total Operating Expenses	135	133	134	127	107	117	114	125	120	119
Selling, General & Admin Expense	51	47	45	41	28	34	34	39	37	36
Research & Development Expense	85	87	89	86	79	83	81	86	83	82
Total Other Income / (Expense), net	3.15	2.45	3.18	6.18	1.58	2.67	2.22	2.53	3.21	2.72
Interest Expense	1.53	1.85	1.66	1.60	1.36	0.94	0.51	0.26	0.28	0.26
Interest & Investment Income	4.67	4.30	4.84	7.78	2.94	3.61	2.73	2.79	3.49	2.98
Income Tax Expense	14	1.58	7.75	12	3.39	-16	-0.39	37	2.01	-2.09
Basic Earnings per Share	$0.62	$0.77	$0.44	$0.35	$0.33	($2.21)	($1.77)	($2.56)	($0.88)	($0.72)
Weighted Average Basic Shares Outstanding	34.08M	35.09M	31.96M	31.61M	31.80M	31.80M	31.91M	32.12M	32.31M	32.19M
Diluted Earnings per Share	$0.60	$0.76	$0.41	$0.33	$0.32	($2.15)	($1.77)	($2.56)	($0.88)	($0.72)
Weighted Average Diluted Shares Outstanding	34.78M	36.04M	33.75M	32.93M	32.08M	31.80M	31.91M	32.12M	32.31M	32.19M
Weighted Average Basic & Diluted Shares Outstanding	33.28M	31.90M	32.00M	31.86M	31.78M	31.90M	31.92M	32.29M	32.45M	32.46M

This table details how cash moves in and out of Silicon Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-28	27	128	-72	30	-24	872	-575	-272	54
Net Cash From Operating Activities	105	129	190	174	22	-8.84	91	141	-30	-14
Net Cash From Continuing Operating Activities	105	129	190	174	22	-8.84	91	141	-30	-14
Net Income / (Loss) Continuing Operations	30	61	47	84	-103	-115	-58	91	-35	-191
Consolidated Net Income / (Loss)	30	61	47	84	19	13	2,117	91	-35	-191
Depreciation Expense	13	13	15	16	15	16	18	23	26	26
Amortization Expense	29	28	37	57	51	64	67	36	26	23
Non-Cash Adjustments To Reconcile Net Income	41	38	45	50	44	51	46	57	64	62
Changes in Operating Assets and Liabilities, net	-6.55	-11	46	-33	14	-25	17	-66	-112	67
Net Cash From Investing Activities	-49	-50	-374	-197	-103	-358	-477	241	470	113
Net Cash From Continuing Investing Activities	-49	-50	-374	-197	-103	-358	-477	241	470	113
Purchase of Property, Plant & Equipment	-18	-20	-17	-36	-23	-19	-30	-27	-23	-12
Purchase of Investments	-107	-185	-636	-396	-425	-520	-1,542	-607	-103	-74
Divestitures	-	-	-	-	-	-	-	0.00	0.00	12
Sale and/or Maturity of Investments	172	162	294	474	345	497	1,095	874	596	186
Net Cash From Financing Activities	-84	-52	313	-49	-30	201	-1,299	-887	-712	-45
Net Cash From Continuing Financing Activities	-84	-52	313	-49	-30	201	-1,299	-887	-712	-45
Repayment of Debt	-95	-5.00	-83	0.00	-1.13	-625	-141	-0.02	-571	-45
Repurchase of Common Equity	-71	-41	0.00	-39	-27	-16	-1,150	-883	-217	-0.02
Issuance of Debt	81	0.00	400	0.00	0.00	845	0.00	0.00	80	0.00
Issuance of Common Equity	17	13	12	13	14	15	14	12	15	16
Other Financing Activities, net	-16	-20	-16	-23	-16	-18	-22	-15	-18	-16
Other Net Changes in Cash	-	-	-	-	140	142	2,556	-69	0.00	0.00
Cash Interest Paid	2.47	2.22	3.86	6.23	6.37	8.66	5.01	4.43	4.47	0.99
Cash Income Taxes Paid	2.16	11	8.93	21	10	7.22	266	132	32	19

This table details how cash moves in and out of Silicon Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-22	17	216	-482	-75	68	-36	49	62	-21
Net Cash From Operating Activities	44	14	-13	-2.22	-33	19	-72	16	32	10
Net Cash From Continuing Operating Activities	44	14	-13	-2.22	-33	19	-72	16	32	10
Net Income / (Loss) Continuing Operations	21	25	14	11	10	-70	-57	-82	-29	-24
Consolidated Net Income / (Loss)	21	25	14	11	10	-70	-57	-82	-29	-24
Depreciation Expense	5.95	6.01	6.24	6.21	6.55	6.72	6.63	6.52	6.15	6.25
Amortization Expense	8.63	7.25	7.03	6.83	6.26	6.21	6.08	6.08	5.44	5.44
Non-Cash Adjustments To Reconcile Net Income	14	17	18	15	5.85	26	14	16	16	16
Changes in Operating Assets and Liabilities, net	-5.67	-42	-58	-41	-62	49	-42	70	33	6.12
Net Cash From Investing Activities	69	200	254	162	10	43	81	40	30	-38
Net Cash From Continuing Investing Activities	69	200	254	162	10	43	81	40	30	-38
Purchase of Property, Plant & Equipment	-7.74	-6.47	-7.66	-6.02	-5.25	-3.87	-2.05	-3.53	-2.21	-3.96
Purchase of Investments	-25	-28	-66	-15	-10	-12	-9.79	-7.91	-11	-45
Sale and/or Maturity of Investments	102	234	328	183	26	59	81	51	43	11
Net Cash From Financing Activities	-103	-197	-25	-641	-52	5.65	-46	-6.40	0.42	6.58
Net Cash From Continuing Financing Activities	-103	-197	-25	-641	-52	5.65	-46	-6.40	0.42	6.58
Repurchase of Common Equity	-103	-202	-18	-183	-16	-	0.00	-	-	-0.02
Issuance of Common Equity	0.00	5.41	0.00	7.79	0.23	6.60	0.34	7.77	1.29	6.95
Other Financing Activities, net	-0.77	-0.66	-6.93	-9.38	-0.93	-0.95	-1.05	-14	-0.87	-0.36

This table presents Silicon Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	1,011	1,082	1,535	1,624	1,675	1,993	2,958	2,169	1,443	1,223
Total Current Assets	423	491	948	827	944	976	2,239	1,461	738	602
Cash & Equivalents	114	141	269	197	227	203	1,075	500	228	282
Short-Term Investments	129	154	495	417	499	522	965	692	212	101
Accounts Receivable	74	74	71	73	76	95	98	71	29	54
Inventories, net	54	60	73	75	73	48	49	100	194	106
Prepaid Expenses	53	62	39	65	69	87	52	98	75	60
Plant, Property, & Equipment, net	131	130	128	139	136	136	147	152	146	132
Total Noncurrent Assets	457	461	460	659	595	882	573	556	559	489
Long-Term Investments	7.13	-	-	-	-	77	78	95	123	76
Goodwill	273	276	288	397	398	376	376	376	376	376
Intangible Assets	121	104	83	171	134	163	119	85	60	36
Total Liabilities & Shareholders' Equity	1,011	1,082	1,535	1,624	1,675	1,993	2,958	2,169	1,443	1,223
Total Liabilities	250	255	582	557	560	794	746	764	234	143
Total Current Liabilities	142	140	162	145	138	284	669	186	164	98
Short-Term Debt	10	-	-	-	0.00	134	451	0.00	45	0.00
Accounts Payable	42	40	39	41	39	55	47	90	57	42
Current Deferred Revenue	35	46	50	22	19	13	14	6.78	2.12	3.07
Other Current Liabilities	-	55	73	81	80	82	157	89	59	52
Total Noncurrent Liabilities	108	115	420	412	422	509	77	579	71	45
Other Noncurrent Operating Liabilities	-	-	-	-	-	80	77	49	71	45
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	761	827	953	1,067	1,115	1,200	2,212	1,405	1,209	1,080
Total Preferred & Common Equity	761	827	953	1,067	1,115	1,200	2,212	1,405	1,209	1,080
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	761	827	953	1,067	1,115	1,200	2,212	1,405	1,209	1,080
Common Stock	14	24	103	108	134	204	0.00	0.00	17	78
Retained Earnings	748	802	851	961	981	994	2,215	1,416	1,193	1,002
Accumulated Other Comprehensive Income / (Loss)	-0.51	0.49	-1.16	-1.57	0.65	1.81	-2.42	-11	-1.03	0.07

This table presents Silicon Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	2,336	2,161	1,519	1,475	1,344	1,250	1,249
Total Current Assets	1,626	1,461	821	774	646	600	614
Cash & Equivalents	483	716	235	160	191	241	303
Short-Term Investments	893	436	271	257	141	98	67
Accounts Receivable	77	88	98	102	33	41	49
Inventories, net	88	133	146	168	198	166	139
Prepaid Expenses	84	88	71	87	83	54	56
Plant, Property, & Equipment, net	152	152	152	151	142	139	135
Total Noncurrent Assets	559	549	545	551	556	511	500
Long-Term Investments	91	94	97	109	126	87	81
Goodwill	376	376	376	376	376	376	376
Intangible Assets	92	78	72	66	53	47	42
Total Liabilities & Shareholders' Equity	2,336	2,161	1,519	1,475	1,344	1,250	1,249
Total Liabilities	785	742	260	215	179	157	168
Total Current Liabilities	206	693	219	165	111	100	118
Short-Term Debt	0.00	530	80	45	0.00	0.00	0.00
Accounts Payable	82	71	55	48	45	39	45
Current Deferred Revenue	12	11	11	10	3.92	3.32	8.48
Other Current Liabilities	112	81	72	62	63	57	65
Total Noncurrent Liabilities	579	49	41	50	67	57	50
Other Noncurrent Operating Liabilities	50	49	41	50	67	57	50
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,552	1,419	1,259	1,260	1,166	1,093	1,081
Total Preferred & Common Equity	1,552	1,419	1,259	1,260	1,166	1,093	1,081
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,552	1,419	1,259	1,260	1,166	1,093	1,081
Common Stock	0.00	0.00	0.00	0.00	30	39	56
Retained Earnings	1,568	1,426	1,263	1,263	1,136	1,054	1,026
Accumulated Other Comprehensive Income / (Loss)	-16	-6.46	-4.09	-2.60	-0.48	-0.25	0.27

This table displays calculated financial ratios and metrics derived from Silicon Laboratories' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.89%	8.19%	10.21%	12.93%	-45.43%	7.84%	41.09%	42.07%	-23.62%	-25.30%
EBITDA Growth	-9.54%	45.11%	27.91%	15.30%	-114.06%	-20.64%	295.70%	238.87%	-84.32%	-519.21%
EBIT Growth	-37.03%	105.61%	28.21%	0.28%	-204.03%	-20.81%	69.34%	463.18%	-120.25%	-585.15%
NOPAT Growth	-20.95%	100.53%	-17.66%	89.69%	-162.86%	-20.81%	69.34%	461.07%	-120.37%	-585.15%
Net Income Growth	-22.19%	107.85%	-23.42%	77.51%	-76.95%	-34.95%	16,797.29%	-95.68%	-137.76%	-453.40%
EPS Growth	-20.69%	110.14%	-24.83%	74.31%	-77.37%	-34.88%	16,964.29%	-94.68%	-142.91%	-444.04%
Operating Cash Flow Growth	-23.28%	22.25%	47.02%	-8.43%	-87.22%	-139.86%	1,131.77%	54.91%	-121.48%	54.17%
Free Cash Flow Firm Growth	-152.61%	188.71%	100.23%	-275.09%	95.23%	891.99%	79.93%	-117.59%	-218.11%	21.98%
Invested Capital Growth	15.07%	2.87%	-5.93%	42.21%	-6.30%	-16.61%	-19.29%	18.67%	6.68%	-9.97%
Revenue Q/Q Growth	-0.29%	3.34%	2.45%	1.70%	-43.17%	60.86%	28.46%	4.99%	-17.89%	15.72%
EBITDA Q/Q Growth	-4.28%	15.24%	8.14%	-2.09%	-116.76%	76.02%	1,250.99%	8.25%	-77.76%	27.00%
EBIT Q/Q Growth	-15.89%	29.98%	8.02%	-8.61%	-243.37%	41.65%	63.97%	21.91%	-133.07%	21.19%
NOPAT Q/Q Growth	-12.66%	28.89%	-32.80%	37.43%	-307.78%	41.65%	63.97%	37.55%	-132.60%	21.19%
Net Income Q/Q Growth	-12.86%	30.72%	-34.64%	31.44%	-21.99%	-5.77%	-0.57%	45.21%	-156.93%	19.40%
EPS Q/Q Growth	-12.66%	29.46%	-34.73%	31.94%	-21.82%	-9.68%	0.19%	22.71%	-159.89%	19.43%
Operating Cash Flow Q/Q Growth	-10.08%	3.42%	15.80%	-10.21%	-86.42%	90.42%	380.77%	-17.08%	13.36%	-152.82%
Free Cash Flow Firm Q/Q Growth	-50.44%	-13.41%	7.58%	16.59%	-110.10%	115.38%	-83.21%	89.87%	47.29%	-2,382.90%
Invested Capital Q/Q Growth	4.29%	7.84%	2.57%	1.25%	0.12%	-36.79%	49.10%	5.64%	-11.31%	-1.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	59.05%	60.42%	59.07%	60.05%	59.14%	57.71%	59.01%	62.74%	58.88%	53.42%
EBITDA Margin	11.46%	15.37%	17.84%	18.21%	-4.69%	-5.25%	7.28%	17.37%	3.56%	-20.00%
Operating Margin	5.00%	9.50%	11.05%	9.81%	-18.71%	-20.96%	-4.56%	11.65%	-3.09%	-28.32%
EBIT Margin	5.00%	9.50%	11.05%	9.81%	-18.71%	-20.96%	-4.56%	11.65%	-3.09%	-28.32%
Profit (Net Income) Margin	4.59%	8.81%	6.12%	9.63%	4.07%	2.45%	293.73%	8.93%	-4.41%	-32.69%
Tax Burden Percent	97.76%	95.35%	61.24%	115.84%	-20.07%	-9.48%	-3,639.71%	72.28%	327.38%	123.38%
Interest Burden Percent	93.89%	97.31%	90.50%	84.69%	108.31%	123.45%	177.16%	106.03%	43.65%	93.55%
Effective Tax Rate	2.24%	4.65%	38.76%	-15.84%	0.00%	0.00%	0.00%	30.41%	0.00%	0.00%
Return on Invested Capital (ROIC)	5.36%	9.90%	8.29%	13.39%	-7.40%	-10.08%	-3.76%	13.90%	-2.53%	-17.64%
ROIC Less NNEP Spread (ROIC-NNEP)	6.48%	10.99%	10.17%	18.93%	-39.57%	-31.23%	-199.25%	13.21%	0.24%	-2.23%
Return on Net Nonoperating Assets (RNNOA)	-1.47%	-2.16%	-3.00%	-5.11%	9.17%	11.16%	127.87%	-8.85%	-0.12%	0.95%
Return on Equity (ROE)	3.90%	7.74%	5.29%	8.28%	1.77%	1.08%	124.11%	5.05%	-2.64%	-16.69%
Cash Return on Invested Capital (CROIC)	-8.66%	7.07%	14.39%	-21.47%	-0.90%	8.03%	17.59%	-3.17%	-8.99%	-7.15%
Operating Return on Assets (OROA)	3.14%	6.33%	6.49%	5.39%	-5.37%	-5.84%	-1.33%	4.65%	-1.34%	-12.42%
Return on Assets (ROA)	2.88%	5.88%	3.60%	5.29%	1.17%	0.68%	85.52%	3.57%	-1.91%	-14.33%
Return on Common Equity (ROCE)	3.90%	7.74%	5.29%	8.28%	1.77%	1.08%	124.11%	5.05%	-2.64%	-16.69%
Return on Equity Simple (ROE_SIMPLE)	3.89%	7.44%	4.94%	7.83%	1.73%	1.04%	95.70%	6.51%	-2.86%	-17.69%
Net Operating Profit after Tax (NOPAT)	32	63	52	99	-62	-75	-23	83	-17	-116
NOPAT Margin	4.89%	9.06%	6.77%	11.37%	-13.10%	-14.67%	-3.19%	8.10%	-2.16%	-19.82%
Net Nonoperating Expense Percent (NNEP)	-1.12%	-1.09%	-1.89%	-5.54%	32.17%	21.15%	195.49%	0.69%	-2.76%	-15.41%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	4.29%	-1.35%	-10.73%
Cost of Revenue to Revenue	40.95%	39.58%	40.93%	39.95%	40.86%	42.29%	40.99%	37.26%	41.12%	46.58%
SG&A Expenses to Revenue	24.89%	22.29%	20.77%	22.79%	34.44%	32.64%	25.67%	18.65%	18.79%	24.89%
R&D to Revenue	29.16%	28.63%	27.25%	27.45%	43.41%	46.03%	37.90%	32.45%	43.18%	56.85%
Operating Expenses to Revenue	54.05%	50.92%	48.02%	50.24%	77.85%	78.67%	63.57%	51.10%	61.97%	81.74%
Earnings before Interest and Taxes (EBIT)	32	66	85	85	-89	-107	-33	119	-24	-165
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	74	107	137	158	-22	-27	52	178	28	-117
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.65	3.28	3.94	3.17	4.53	4.65	3.75	3.21	3.48	3.84
Price to Tangible Book Value (P/TBV)	5.50	6.07	6.46	6.79	8.68	8.46	4.83	4.78	5.44	6.22
Price to Revenue (P/Rev)	3.13	3.89	4.89	3.90	10.67	10.92	11.51	4.41	5.37	7.10
Price to Earnings (P/E)	68.21	44.13	79.81	40.52	262.33	445.37	3.92	49.40	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.47%	2.27%	1.25%	2.47%	0.38%	0.22%	25.52%	2.02%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.00	3.92	5.61	3.68	5.86	7.90	12.14	5.80	5.33	5.93
Enterprise Value to Revenue (EV/Rev)	2.92	3.63	4.44	3.67	10.03	10.46	9.20	3.67	4.71	6.31
Enterprise Value to EBITDA (EV/EBITDA)	25.53	23.63	24.90	20.15	0.00	0.00	126.30	21.13	132.17	0.00
Enterprise Value to EBIT (EV/EBIT)	58.51	38.23	40.18	37.39	0.00	0.00	0.00	31.51	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	59.85	40.10	65.61	32.27	0.00	0.00	0.00	45.28	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	17.89	19.66	18.02	18.36	214.19	0.00	72.69	26.60	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	56.13	37.78	0.00	0.00	89.43	61.66	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.16	0.14	0.44	0.39	0.38	0.47	0.20	0.38	0.04	0.00
Long-Term Debt to Equity	0.14	0.14	0.44	0.39	0.38	0.36	0.00	0.38	0.00	0.00
Financial Leverage	-0.23	-0.20	-0.29	-0.27	-0.23	-0.36	-0.64	-0.67	-0.49	-0.43
Leverage Ratio	1.35	1.32	1.47	1.56	1.51	1.58	1.45	1.42	1.38	1.16
Compound Leverage Factor	1.27	1.28	1.33	1.32	1.64	1.96	2.57	1.50	0.60	1.09
Debt to Total Capital	13.43%	12.23%	30.58%	27.86%	27.46%	31.95%	16.92%	27.37%	3.59%	0.00%
Short-Term Debt to Total Capital	1.14%	0.00%	0.00%	0.00%	0.00%	7.63%	16.92%	0.00%	3.59%	0.00%
Long-Term Debt to Total Capital	12.29%	12.23%	30.58%	27.86%	27.46%	24.33%	0.00%	27.37%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.57%	87.77%	69.42%	72.14%	72.54%	68.05%	83.08%	72.63%	96.41%	100.00%
Debt to EBITDA	1.60	1.07	3.06	2.61	-18.99	-21.01	8.59	2.98	1.61	0.00
Net Debt to EBITDA	-1.79	-1.68	-2.51	-1.28	13.67	8.87	-31.75	-4.26	-18.56	0.00
Long-Term Debt to EBITDA	1.46	1.07	3.06	2.61	-18.99	-15.99	0.00	2.98	0.00	0.00
Debt to NOPAT	3.75	1.82	8.07	4.18	-6.80	-7.52	-19.60	6.38	-2.66	0.00
Net Debt to NOPAT	-4.19	-2.85	-6.62	-2.04	4.90	3.17	72.50	-9.12	30.61	0.00
Long-Term Debt to NOPAT	3.43	1.82	8.07	4.18	-6.80	-5.72	0.00	6.38	0.00	0.00
Altman Z-Score	6.95	8.66	5.95	5.69	6.92	5.41	8.57	5.82	12.88	19.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.97	3.51	5.84	5.71	6.85	3.43	3.35	7.87	4.51	6.15
Quick Ratio	2.22	2.64	5.15	4.74	5.82	2.88	3.20	6.80	2.86	4.46
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-51	45	90	-158	-7.54	60	108	-19	-60	-47
Operating Cash Flow to CapEx	596.86%	653.44%	1,101.10%	488.51%	95.48%	-45.80%	306.70%	532.61%	-133.09%	-118.40%
Free Cash Flow to Firm to Interest Expense	-17.99	17.45	6.40	-8.04	-0.37	1.75	3.46	-2.81	-10.83	-35.83
Operating Cash Flow to Interest Expense	37.29	49.83	13.41	8.81	1.10	-0.26	2.94	21.01	-5.46	-10.62
Operating Cash Flow Less CapEx to Interest Expense	31.04	42.20	12.20	7.01	-0.05	-0.82	1.98	17.07	-9.57	-19.59
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.63	0.67	0.59	0.55	0.29	0.28	0.29	0.40	0.43	0.44
Accounts Receivable Turnover	8.96	9.43	10.55	12.01	6.37	5.98	7.45	12.07	15.53	13.95
Inventory Turnover	4.96	4.87	4.74	4.68	2.62	3.57	6.08	5.10	2.18	1.82
Fixed Asset Turnover	4.89	5.35	5.98	6.51	3.45	3.76	5.11	6.86	5.25	4.20
Accounts Payable Turnover	6.52	6.76	8.02	8.67	4.84	4.61	5.78	5.56	4.37	5.45
Days Sales Outstanding (DSO)	40.75	38.72	34.60	30.39	57.33	61.01	48.98	30.25	23.50	26.16
Days Inventory Outstanding (DIO)	73.62	75.00	76.97	77.92	139.56	102.13	60.02	71.62	167.20	201.10
Days Payable Outstanding (DPO)	56.02	54.00	45.49	42.10	75.49	79.26	63.17	65.62	83.60	67.01
Cash Conversion Cycle (CCC)	58.35	59.71	66.08	66.21	121.40	83.87	45.83	36.25	107.10	160.25
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	629	647	609	866	811	676	546	648	691	622
Invested Capital Turnover	1.10	1.09	1.22	1.18	0.57	0.69	1.18	1.72	1.17	0.89
Increase / (Decrease) in Invested Capital	82	18	-38	257	-55	-135	-130	102	43	-69
Enterprise Value (EV)	1,886	2,534	3,414	3,186	4,750	5,343	6,629	3,758	3,686	3,688
Market Capitalization	2,018	2,714	3,759	3,387	5,054	5,581	8,295	4,515	4,203	4,146
Book Value per Share	$18.31	$19.81	$22.39	$24.74	$25.71	$27.38	$55.05	$42.21	$38.03	$33.28
Tangible Book Value per Share	$8.83	$10.71	$13.66	$11.57	$13.43	$15.06	$42.73	$28.35	$24.32	$20.56
Total Capital	879	942	1,373	1,480	1,537	1,763	2,663	1,935	1,254	1,080
Total Debt	118	115	420	412	422	563	451	530	45	0.00
Total Long-Term Debt	108	115	420	412	422	429	0.00	530	0.00	0.00
Net Debt	-132	-180	-344	-202	-304	-238	-1,666	-757	-518	-458
Capital Expenditures (CapEx)	18	20	17	36	23	19	30	27	23	12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	48	56	21	68	80	101	-19	84	180	122
Debt-free Net Working Capital (DFNWC)	291	351	785	682	806	826	2,020	1,276	619	504
Net Working Capital (NWC)	281	351	785	682	806	691	1,570	1,276	574	504
Net Nonoperating Expense (NNE)	1.93	1.70	4.94	15	-81	-87	-2,140	-8.41	18	75
Net Nonoperating Obligations (NNO)	-132	-180	-344	-202	-304	-523	-1,666	-757	-518	-458
Total Depreciation and Amortization (D&A)	42	41	52	73	66	80	85	59	52	49
Debt-free, Cash-free Net Working Capital to Revenue	7.42%	8.04%	2.77%	7.83%	16.92%	19.79%	-2.62%	8.17%	23.03%	20.87%
Debt-free Net Working Capital to Revenue	45.10%	50.34%	102.14%	78.52%	170.15%	161.63%	280.27%	124.56%	79.18%	86.27%
Net Working Capital to Revenue	43.55%	50.34%	102.14%	78.52%	170.15%	135.31%	217.76%	124.56%	73.42%	86.27%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.70	$1.47	$1.11	$1.94	$0.44	$0.29	$49.44	$2.61	($1.09)	($5.93)
Adjusted Weighted Average Basic Shares Outstanding	42.31M	41.71M	42.45M	43.16M	43.35M	43.78M	42.83M	35.09M	31.80M	32.19M
Adjusted Diluted Earnings per Share	$0.69	$1.45	$1.09	$1.90	$0.43	$0.28	$47.78	$2.54	($1.09)	($5.93)
Adjusted Weighted Average Diluted Shares Outstanding	42.95M	42.38M	43.33M	44.04M	44.29M	44.37M	44.32M	36.04M	31.80M	32.19M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	41.55M	41.89M	42.71M	43.09M	43.50M	43.93M	38.20M	31.90M	31.90M	32.46M
Normalized Net Operating Profit after Tax (NOPAT)	32	63	52	60	-62	-75	-23	83	-17	-116
Normalized NOPAT Margin	4.89%	9.06%	6.77%	6.87%	-13.10%	-14.67%	-3.19%	8.10%	-2.16%	-19.82%
Pre Tax Income Margin	4.69%	9.25%	10.00%	8.31%	-20.26%	-25.88%	-8.07%	12.35%	-1.35%	-26.49%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	11.40	25.62	6.01	4.33	-4.38	-3.14	-1.06	17.74	-4.35	-126.33
NOPAT to Interest Expense	11.14	24.43	3.68	5.01	-3.07	-2.20	-0.74	12.35	-3.04	-88.43
EBIT Less CapEx to Interest Expense	5.15	17.99	4.80	2.52	-5.53	-3.70	-2.02	13.79	-8.45	-135.30
NOPAT Less CapEx to Interest Expense	4.90	16.80	2.46	3.21	-4.21	-2.76	-1.70	8.40	-7.15	-97.40
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	241.49%	65.93%	0.00%	46.99%	138.68%	129.97%	54.31%	966.53%	-629.09%	-0.01%

This table displays calculated financial ratios and metrics derived from Silicon Laboratories' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	45.98%	23.31%	5.55%	-6.95%	-24.48%	-66.25%	-56.90%	-40.63%	-18.34%	91.43%
EBITDA Growth	273.68%	56.97%	-33.77%	-34.52%	-44.15%	-261.18%	-241.35%	-217.28%	-172.41%	71.85%
EBIT Growth	425.85%	812.28%	-41.72%	-45.29%	-59.58%	-403.68%	-402.12%	-379.73%	-343.17%	60.84%
NOPAT Growth	367.57%	1,125.67%	-40.89%	-61.40%	-46.95%	-326.03%	-420.79%	-515.18%	-325.63%	60.84%
Net Income Growth	-98.99%	918.62%	-39.03%	-50.50%	-50.72%	-375.17%	-504.71%	-849.88%	-375.45%	65.86%
EPS Growth	-98.72%	162.07%	-29.31%	-45.00%	-46.67%	-382.89%	-531.71%	-875.76%	-375.00%	66.51%
Operating Cash Flow Growth	3.62%	-67.74%	-115.59%	-20.98%	-175.80%	33.76%	-440.66%	826.76%	194.73%	-45.36%
Free Cash Flow Firm Growth	-132.94%	-159.90%	-126.93%	-177.01%	31.75%	-19.13%	74.70%	122.68%	181.80%	151.74%
Invested Capital Growth	67.48%	18.67%	36.74%	28.57%	27.07%	6.68%	0.45%	-9.36%	-19.13%	-9.97%
Revenue Q/Q Growth	2.53%	-4.63%	-4.10%	-0.78%	-16.79%	-57.38%	22.49%	36.66%	14.47%	-0.09%
EBITDA Q/Q Growth	-2.86%	-16.67%	-12.05%	-8.03%	-17.14%	-340.49%	22.87%	23.69%	48.84%	6.52%
EBIT Q/Q Growth	-3.68%	-20.34%	-18.70%	-12.29%	-28.83%	-698.44%	19.12%	18.79%	38.14%	3.64%
NOPAT Q/Q Growth	-17.17%	30.33%	-43.01%	-37.25%	13.84%	-655.27%	19.12%	18.79%	38.14%	3.64%
Net Income Q/Q Growth	-5.13%	20.77%	-44.93%	-21.56%	-5.55%	-774.40%	19.00%	-45.34%	65.31%	16.42%
EPS Q/Q Growth	0.00%	26.67%	-46.05%	-19.51%	-3.03%	-771.88%	17.67%	-44.63%	65.63%	18.18%
Operating Cash Flow Q/Q Growth	2,500.11%	-68.53%	-195.83%	83.28%	-1,403.83%	155.52%	-487.33%	122.47%	96.03%	-67.97%
Free Cash Flow Firm Q/Q Growth	-213.80%	65.49%	-122.21%	11.75%	-0.85%	39.77%	52.81%	179.11%	263.74%	-61.90%
Invested Capital Q/Q Growth	7.14%	5.64%	8.61%	4.59%	5.89%	-11.31%	2.27%	-5.62%	-5.52%	-1.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	61.37%	61.13%	62.35%	58.72%	58.41%	50.58%	51.77%	52.68%	54.28%	54.27%
EBITDA Margin	16.61%	14.51%	13.31%	12.33%	12.28%	-69.30%	-43.64%	-24.37%	-10.89%	-10.19%
Operating Margin	11.20%	9.36%	7.93%	7.01%	6.00%	-84.19%	-55.59%	-33.03%	-17.85%	-17.22%
EBIT Margin	11.20%	9.36%	7.93%	7.01%	6.00%	-84.19%	-55.59%	-33.03%	-17.85%	-17.22%
Profit (Net Income) Margin	7.78%	9.86%	5.66%	4.47%	5.08%	-80.36%	-53.14%	-56.52%	-17.13%	-14.33%
Tax Burden Percent	62.93%	95.61%	61.39%	46.92%	75.01%	99.07%	99.32%	180.59%	107.57%	91.95%
Interest Burden Percent	110.41%	110.18%	116.25%	136.02%	112.92%	96.35%	96.24%	94.74%	89.20%	90.51%
Effective Tax Rate	42.52%	5.95%	34.07%	52.84%	24.56%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	12.82%	15.10%	8.90%	5.15%	6.19%	-68.85%	-35.41%	-17.88%	-8.96%	-10.73%
ROIC Less NNEP Spread (ROIC-NNEP)	12.60%	14.87%	8.81%	4.78%	6.03%	-65.93%	-32.84%	-7.65%	-7.30%	-9.95%
Return on Net Nonoperating Assets (RNNOA)	-9.66%	-9.96%	-5.68%	-2.60%	-3.04%	32.15%	14.92%	3.08%	2.91%	4.24%
Return on Equity (ROE)	3.16%	5.13%	3.23%	2.55%	3.15%	-36.70%	-20.49%	-14.79%	-6.05%	-6.49%
Cash Return on Invested Capital (CROIC)	-38.13%	-3.17%	-18.91%	-15.79%	-16.39%	-8.99%	-10.66%	-6.95%	0.29%	-7.15%
Operating Return on Assets (OROA)	3.66%	3.74%	3.29%	3.63%	3.00%	-36.46%	-20.36%	-12.94%	-6.62%	-7.55%
Return on Assets (ROA)	2.54%	3.94%	2.35%	2.32%	2.54%	-34.80%	-19.46%	-22.14%	-6.35%	-6.28%
Return on Common Equity (ROCE)	3.16%	5.13%	3.23%	2.55%	3.15%	-36.70%	-20.49%	-14.79%	-6.05%	-6.49%
Return on Equity Simple (ROE_SIMPLE)	4.06%	0.00%	5.81%	5.66%	4.81%	0.00%	-9.01%	-18.13%	-21.91%	0.00%
Net Operating Profit after Tax (NOPAT)	17	23	13	8.10	9.22	-51	-41	-34	-21	-20
NOPAT Margin	6.44%	8.80%	5.23%	3.31%	4.52%	-58.93%	-38.91%	-23.12%	-12.50%	-12.05%
Net Nonoperating Expense Percent (NNEP)	0.23%	0.22%	0.10%	0.37%	0.16%	-2.92%	-2.58%	-10.23%	-1.65%	-0.78%
Return On Investment Capital (ROIC_SIMPLE)	-	1.17%	-	-	-	-4.08%	-	-	-	-1.86%
Cost of Revenue to Revenue	38.63%	38.87%	37.65%	41.28%	41.59%	49.42%	48.23%	47.32%	45.72%	45.73%
SG&A Expenses to Revenue	18.80%	18.10%	18.19%	16.62%	13.63%	38.73%	31.54%	26.62%	22.11%	21.90%
R&D to Revenue	31.36%	33.67%	36.22%	35.08%	38.79%	96.04%	75.82%	59.10%	50.02%	49.59%
Operating Expenses to Revenue	50.17%	51.77%	54.41%	51.71%	52.42%	134.77%	107.36%	85.72%	72.13%	71.49%
Earnings before Interest and Taxes (EBIT)	30	24	20	17	12	-73	-59	-48	-30	-29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	45	37	33	30	25	-60	-46	-35	-18	-17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.72	3.21	3.93	4.01	2.93	3.48	3.92	3.23	3.48	3.84
Price to Tangible Book Value (P/TBV)	3.90	4.78	5.79	6.23	4.52	5.44	6.21	5.28	5.67	6.22
Price to Revenue (P/Rev)	4.33	4.41	5.39	4.95	3.88	5.37	7.12	6.51	7.45	7.10
Price to Earnings (P/E)	67.12	49.40	67.73	70.81	60.90	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.49%	2.02%	1.48%	1.41%	1.64%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.36	5.80	6.92	6.15	4.12	5.33	5.81	4.66	5.25	5.93
Enterprise Value to Revenue (EV/Rev)	3.37	3.67	4.70	4.44	3.37	4.71	6.40	5.73	6.56	6.31
Enterprise Value to EBITDA (EV/EBITDA)	20.00	21.13	30.22	31.16	25.61	132.17	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	33.59	31.51	46.27	49.70	43.98	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	54.46	45.28	65.91	75.10	61.94	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	19.29	26.60	113.81	106.70	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,610.50	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.34	0.38	0.37	0.06	0.04	0.04	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.34	0.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.77	-0.67	-0.64	-0.54	-0.50	-0.49	-0.45	-0.40	-0.40	-0.43
Leverage Ratio	1.42	1.42	1.46	1.38	1.36	1.38	1.36	1.18	1.16	1.16
Compound Leverage Factor	1.57	1.56	1.70	1.87	1.53	1.33	1.31	1.12	1.04	1.05
Debt to Total Capital	25.43%	27.37%	27.19%	5.98%	3.45%	3.59%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	27.19%	5.98%	3.45%	3.59%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	25.43%	27.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	74.57%	72.63%	72.81%	94.02%	96.55%	96.41%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	3.22	2.98	3.29	0.55	0.36	1.61	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-5.71	-4.26	-4.44	-3.60	-3.83	-18.56	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	3.22	2.98	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	8.77	6.38	7.18	1.33	0.87	-2.66	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-15.55	-9.12	-9.69	-8.68	-9.27	30.61	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	8.77	6.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.36	5.67	6.38	14.00	12.67	12.77	17.34	15.47	15.40	19.48
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.90	7.87	2.11	3.76	4.68	4.51	5.80	5.99	5.19	6.15
Quick Ratio	7.06	6.80	1.79	2.76	3.14	2.86	3.28	3.80	3.54	4.46
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-230	-79	-176	-155	-157	-94	-45	35	128	49
Operating Cash Flow to CapEx	569.39%	214.25%	-173.44%	-36.88%	-635.78%	478.50%	-3,507.57%	457.05%	1,432.38%	255.59%
Free Cash Flow to Firm to Interest Expense	-150.44	-42.87	-106.37	-97.40	-115.36	-100.14	-87.56	134.05	461.30	187.94
Operating Cash Flow to Interest Expense	28.84	7.49	-8.02	-1.39	-24.57	19.66	-141.06	61.35	113.77	38.96
Operating Cash Flow Less CapEx to Interest Expense	23.78	4.00	-12.64	-5.16	-28.43	15.55	-145.08	47.92	105.82	23.72
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.40	0.41	0.52	0.50	0.43	0.37	0.39	0.37	0.44
Accounts Receivable Turnover	13.07	12.07	12.43	11.96	10.66	15.53	10.67	7.78	6.69	13.95
Inventory Turnover	4.91	5.10	4.20	3.63	2.96	2.18	1.69	1.59	1.56	1.82
Fixed Asset Turnover	6.61	6.86	6.91	6.75	6.30	5.25	4.36	3.72	3.53	4.20
Accounts Payable Turnover	5.19	5.56	5.84	5.29	5.84	4.37	4.83	5.25	5.16	5.45
Days Sales Outstanding (DSO)	27.93	30.25	29.38	30.52	34.25	23.50	34.21	46.93	54.58	26.16
Days Inventory Outstanding (DIO)	74.32	71.62	86.89	100.60	123.36	167.20	215.99	229.54	234.39	201.10
Days Payable Outstanding (DPO)	70.33	65.62	62.53	68.95	62.52	83.60	75.60	69.54	70.78	67.01
Cash Conversion Cycle (CCC)	31.91	36.25	53.74	62.17	95.09	107.10	174.60	206.93	218.18	160.25
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	613	648	704	736	779	691	707	667	630	622
Invested Capital Turnover	1.99	1.72	1.70	1.56	1.37	1.17	0.91	0.77	0.72	0.89
Increase / (Decrease) in Invested Capital	247	102	189	164	166	43	3.17	-69	-149	-69
Enterprise Value (EV)	3,286	3,758	4,869	4,524	3,212	3,686	4,109	3,106	3,312	3,688
Market Capitalization	4,225	4,515	5,585	5,047	3,693	4,203	4,567	3,532	3,763	4,146
Book Value per Share	$45.34	$42.21	$44.50	$39.34	$39.54	$38.03	$36.53	$34.24	$33.49	$33.28
Tangible Book Value per Share	$31.66	$28.35	$30.24	$25.33	$25.66	$24.32	$23.06	$20.96	$20.54	$20.56
Total Capital	2,081	1,935	1,950	1,339	1,305	1,254	1,166	1,093	1,081	1,080
Total Debt	529	530	530	80	45	45	0.00	0.00	0.00	0.00
Total Long-Term Debt	529	530	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-938	-757	-716	-523	-481	-518	-459	-426	-451	-458
Capital Expenditures (CapEx)	7.74	6.47	7.66	6.02	5.25	3.87	2.05	3.53	2.21	3.96
Debt-free, Cash-free Net Working Capital (DFCFNWC)	44	84	145	177	236	180	202	161	126	122
Debt-free Net Working Capital (DFNWC)	1,420	1,276	1,298	682	653	619	535	500	496	504
Net Working Capital (NWC)	1,420	1,276	767	602	608	574	535	500	496	504
Net Nonoperating Expense (NNE)	-3.63	-2.72	-1.06	-2.86	-1.13	19	15	49	7.71	3.78
Net Nonoperating Obligations (NNO)	-938	-757	-716	-523	-481	-518	-459	-426	-451	-458
Total Depreciation and Amortization (D&A)	15	13	13	13	13	13	13	13	12	12
Debt-free, Cash-free Net Working Capital to Revenue	4.46%	8.17%	14.02%	17.33%	24.80%	23.03%	31.48%	29.64%	24.98%	20.87%
Debt-free Net Working Capital to Revenue	145.57%	124.56%	125.11%	66.98%	68.58%	79.18%	83.32%	92.18%	98.19%	86.27%
Net Working Capital to Revenue	145.57%	124.56%	74.00%	59.13%	63.86%	73.42%	83.32%	92.18%	98.19%	86.27%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.62	$0.77	$0.44	$0.35	$0.33	($2.21)	($1.77)	($2.56)	($0.88)	($0.72)
Adjusted Weighted Average Basic Shares Outstanding	34.08M	35.09M	31.96M	31.61M	31.80M	31.80M	31.91M	32.12M	32.31M	32.19M
Adjusted Diluted Earnings per Share	$0.60	$0.76	$0.41	$0.33	$0.32	($2.15)	($1.77)	($2.56)	($0.88)	($0.72)
Adjusted Weighted Average Diluted Shares Outstanding	34.78M	36.04M	33.75M	32.93M	32.08M	31.80M	31.91M	32.12M	32.31M	32.19M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.28M	31.90M	32.00M	31.86M	31.78M	31.90M	31.92M	32.29M	32.45M	32.46M
Normalized Net Operating Profit after Tax (NOPAT)	17	23	13	12	9.22	-51	-41	-34	-21	-20
Normalized NOPAT Margin	6.44%	8.80%	5.23%	4.91%	4.52%	-58.93%	-38.91%	-23.12%	-12.50%	-12.05%
Pre Tax Income Margin	12.37%	10.31%	9.22%	9.54%	6.77%	-81.11%	-53.50%	-31.30%	-15.93%	-15.58%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	19.79	13.02	11.82	10.76	8.99	-77.53	-116.18	-182.59	-106.86	-110.10
NOPAT to Interest Expense	11.38	12.25	7.79	5.07	6.78	-54.27	-81.32	-127.81	-74.80	-77.07
EBIT Less CapEx to Interest Expense	14.73	9.52	7.20	6.98	5.13	-81.64	-120.20	-196.01	-114.81	-125.35
NOPAT Less CapEx to Interest Expense	6.31	8.75	3.17	1.30	2.92	-58.38	-85.35	-141.23	-82.75	-92.32
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	1,816.51%	966.53%	901.33%	709.12%	690.83%	-629.09%	-190.01%	-8.10%	0.00%	-0.01%

Frequently Asked Questions About Silicon Laboratories' Financials

When does Silicon Laboratories's financial year end?

According to the most recent income statement we have on file, Silicon Laboratories' fiscal year ends in December. Their fiscal year 2024 ended on December 28, 2024.

How has Silicon Laboratories' net income changed over the last 9 years?

Silicon Laboratories' net income appears to be on an upward trend, with a most recent value of -$191.01 million in 2024, falling from $29.59 million in 2015. The previous period was -$34.52 million in 2023.

What is Silicon Laboratories's operating income?

Silicon Laboratories's total operating income in 2024 was -$165.49 million, based on the following breakdown:

Total Gross Profit: $312.19 million
Total Operating Expenses: $477.68 million

How has Silicon Laboratories revenue changed over the last 9 years?

Over the last 9 years, Silicon Laboratories' total revenue changed from $644.83 million in 2015 to $584.39 million in 2024, a change of -9.4%.

How much debt does Silicon Laboratories have?

Silicon Laboratories' total liabilities were at $142.65 million at the end of 2024, a 39.1% decrease from 2023, and a 43.0% decrease since 2015.

How much cash does Silicon Laboratories have?

In the past 9 years, Silicon Laboratories' cash and equivalents has ranged from $114.09 million in 2015 to $1.07 billion in 2021, and is currently $281.61 million as of their latest financial filing in 2024.

How has Silicon Laboratories' book value per share changed over the last 9 years?

Over the last 9 years, Silicon Laboratories' book value per share changed from 18.31 in 2015 to 33.28 in 2024, a change of 81.8%.

Related Companies

This page (NASDAQ:SLAB) was last updated on 4/26/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silicon Laboratories (SLAB) Financials

Frequently Asked Questions About Silicon Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silicon Laboratories (SLAB) Financials

Annual Income Statements for Silicon Laboratories

Quarterly Income Statements for Silicon Laboratories

Annual Cash Flow Statements for Silicon Laboratories

Quarterly Cash Flow Statements for Silicon Laboratories

Annual Balance Sheets for Silicon Laboratories

Quarterly Balance Sheets for Silicon Laboratories

Annual Metrics and Ratios for Silicon Laboratories

Quarterly Metrics and Ratios for Silicon Laboratories

Frequently Asked Questions About Silicon Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools